Suppr超能文献

采用刀豆球蛋白 A 包裹壳聚糖纳米粒靶向递送短抗菌肽(CM11)治疗幽门螺杆菌胃感染。

Targeted delivery of a short antimicrobial peptide (CM11) against Helicobacter pylori gastric infection using concanavalin A-coated chitosan nanoparticles.

机构信息

Tissue Engineering and Regenerative Medicine Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Research and Development Unit, Varia Hooman Kara Company, Tehran, Iran.

出版信息

J Mater Sci Mater Med. 2023 Aug 31;34(9):44. doi: 10.1007/s10856-023-06748-w.

Abstract

Helicobacter pylori is the cause of most cases of stomach ulcers and also causes some digestive cancers. The emergence and spread of antibiotic-resistant strains of H. pylori is one of the most important challenges in the treatment of its infections. The present study aims to develop a concanavalin A (ConA) coated chitosan (CS) nanocarrier-based drug delivery for the targeted release of peptides to the site of H. pylori infection. Accordingly, chitosan was used as an encapsulating agent for CM11 peptide delivery by applying ionotropic gelation method. Con-A was used for coating CS nanoparticles to target H. pylori. The CS NPs and ConA-CS NPs were characterized by FTIR, dynamic light scattering (DLS), and scanning electron microscopy (SEM). The MIC of CM11-loaded ConA-CS NPs against H. pylori SS1 strain was analyzed in vitro. In order to evaluate the treatment efficiency in vivo, a gastric infection model of H. pylori SS1 strain was established in mice and histopathological studies and IL-1β cytokine assay were performed. Based on the results, the size frequency for CS NPs and ConA-CS NPs was about 200 and 350 nm, respectively. The prepared CM11-loaded ConA-CS NPs exhibited antibacterial activity against H. pylori SS1 strain with a concentration of 32 µg/ml. The highest healing process was observed in synthesized CM11-loaded ConA-CS NPs treatments and a significant decrease in IL-1β was observed. Our findings highlight the potential of chitosan nanoparticles as a drug delivery vehicle in the treatment of gastric infection model of H. pylori SS1 strain.

摘要

幽门螺杆菌是大多数胃溃疡的病因,也是一些消化道癌症的病因。幽门螺杆菌抗生素耐药株的出现和传播是其感染治疗的最重要挑战之一。本研究旨在开发一种伴刀豆球蛋白 A(ConA)涂层壳聚糖(CS)纳米载体药物递送系统,用于将肽靶向递送到幽门螺杆菌感染部位。因此,壳聚糖被用作 CM11 肽递送的包封剂,通过离子凝胶化方法应用。Con-A 用于 CS 纳米颗粒的涂层以靶向幽门螺杆菌。通过傅里叶变换红外光谱(FTIR)、动态光散射(DLS)和扫描电子显微镜(SEM)对 CS NPs 和 ConA-CS NPs 进行了表征。分析了载有 CM11 的 ConA-CS NPs 对幽门螺杆菌 SS1 株的体外 MIC。为了评估体内治疗效果,在小鼠中建立了幽门螺杆菌 SS1 株的胃感染模型,并进行了组织病理学研究和 IL-1β 细胞因子测定。结果表明,CS NPs 和 ConA-CS NPs 的大小频率分别约为 200nm 和 350nm。载有 CM11 的 ConA-CS NPs 对幽门螺杆菌 SS1 株具有抗菌活性,浓度为 32µg/ml。在合成的载有 CM11 的 ConA-CS NPs 治疗中观察到最高的愈合过程,并观察到 IL-1β 显著下降。我们的研究结果强调了壳聚糖纳米颗粒作为治疗幽门螺杆菌 SS1 株胃感染模型的药物递送载体的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81e7/10471652/e3b3e9183f69/10856_2023_6748_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验